Cargando…

Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis

BACKGROUND: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis compared their effectiveness and safety. METHODS: We searched systematically in PubMed, ScienceDirect, The Cochrane Li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wenxiong, Wei, Yiping, Yu, Dongliang, Xu, Jianjun, Peng, Jinhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916648/ https://www.ncbi.nlm.nih.gov/pubmed/29668619 http://dx.doi.org/10.1097/MD.0000000000010460

Ejemplares similares

Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
por: Zhang, Wenxiong, et al.
Publicado: (2018)

Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials
por: Deng, Huan, et al.
Publicado: (2020)

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review
por: Dong, Yong, et al.
Publicado: (2021)

A meta-analysis comparing stereotactic body radiotherapy vs conventional radiotherapy in inoperable stage I non-small cell lung cancer
por: Li, Can, et al.
Publicado: (2020)

The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis
por: Zhou, Jian-Guo, et al.
Publicado: (2015)

The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis
por: Ma, Hu, et al.
Publicado: (2016)

Nivolumab provides improved effectiveness and safety compared with docetaxel as a second‐line treatment for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Xu, Zheng, et al.
Publicado: (2019)

Potential roles of tumor microenvironment in gefitinib-resistant non-small cell lung cancer: A narrative review
por: Chen, Mu-Tong, et al.
Publicado: (2023)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Renin-Angiotensin System Blockers May Prolong Survival of Metastatic Non-Small Cell Lung Cancer Patients Receiving Erlotinib
por: Aydiner, Adnan, et al.
Publicado: (2015)

Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature
por: Guo, Qiang, et al.
Publicado: (2023)

Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs
por: Li, Dailong, et al.
Publicado: (2022)

Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study
por: Wu, Bo, et al.
Publicado: (2022)

Erlotinib Plus Capecitabine as First-Line Treatment for Older Chinese Patients With Advanced Adenocarcinoma of the Lung (C-TONG0807): An Open-Label, Single Arm, Multicenter Phase II Study
por: Zhao, Hong-Yun, et al.
Publicado: (2015)

Pulmonary function protection by single-port thoracoscopic segmental lung resection in elderly patients with IA non-small cell lung cancer: A differential matched analysis
por: Wang, Silin, et al.
Publicado: (2023)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis
por: Wu, Lin-guang-jin, et al.
Publicado: (2021)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Efficacy and safety of chemoradiation therapy compared with chemotherapy for esophageal carcinoma: An updated meta-analysis of randomized controlled trials
por: Liu, Jinyuan, et al.
Publicado: (2017)

Clinical efficacy and safety of Huachansu injection combination with platinum-based chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials
por: Tan, Xinmei, et al.
Publicado: (2021)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Thoracotomy is better than thoracoscopic lobectomy in the lymph node dissection of lung cancer: a systematic review and meta-analysis
por: Zhang, Wenxiong, et al.
Publicado: (2016)

Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Sen, Fatma, et al.
Publicado: (2016)

Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report
por: Bie, Yanan, et al.
Publicado: (2021)

Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis
por: Chen, Zhenguang, et al.
Publicado: (2015)

Efficacy and safety of elemene combined with chemotherapy in advanced gastric cancer: A Meta-analysis
por: Liu, Ying, et al.
Publicado: (2020)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety
por: Ye, Haiyong, et al.
Publicado: (2021)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis
por: Hu, Yongqi, et al.
Publicado: (2022)

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
por: Emery, Ivette F, et al.
Publicado: (2009)

Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies
por: He, Liyun, et al.
Publicado: (2019)

Concurrent vs sequential chemoradiotherapy for patients with advanced non–small-cell lung cancer: A meta-analysis of randomized controlled trials
por: Xiao, Wei, et al.
Publicado: (2021)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Li, Dailong, et al.
Publicado: (2023)

A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
por: Wang, Cuihua, et al.
Publicado: (2016)

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials
por: Li, Dailong, et al.
Publicado: (2022)

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer
por: Anzai, Masaki, et al.
Publicado: (2017)

S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer: A systematic review and meta-analysis protocol
por: Liu, Feiyu, et al.
Publicado: (2018)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_5n904p8t6jbaooae6ulrj4odkg